Abstract
Liver transplantation (LT) for hepatocellular carcinoma (HCC) is the treatment of choice for patients with tumor characteristics within the Milan criteria associated with Child B or C cirrhosis. LT provides the best cure for both the tumor and the cirrhosis.
There have been several emerging reports that new-onset diabetes mellitus (NODM) after transplantation (NODAT) is one of the most negative predictive factors for low survival rate and related co-morbidities. Little is known about the onset of NODM in post-transplant patients and, overall, whether the pathogenesis of NODM differs from that known for the general population. Principally, it is still unknown whether NODAT is related to the primary hepatic disease, the surgical procedures, immunosuppressive treatments, or is it due to the donor liver. This review will focus on the identification of factors, in the setting of LT, which may lead to the development of NODM. Early prevention of these factors may abate the incidence of NODM and positively impact survival rate, and thus ameliorate the worsening of cardiovascular risk factors which usually occur after LT.Keywords: Liver transplantation, metabolic syndrome, new-onset diabetes mellitus, HCV, immunosuppressive therapy, nonalcoholic steatohepatitis, insulin resistance, liver surgery
Current Diabetes Reviews
Title:New-onset Diabetes Mellitus: Predictive Factors and Impact on the Outcome of Patients Undergoing Liver Transplantation
Volume: 9 Issue: 1
Author(s): Gerardo Sarno, Rucha J. Mehta, Rodolfo Guardado-Mendoza, Lilia M. Jimenez-Ceja, Paride De Rosa and Giovanna Muscogiuri
Affiliation:
Keywords: Liver transplantation, metabolic syndrome, new-onset diabetes mellitus, HCV, immunosuppressive therapy, nonalcoholic steatohepatitis, insulin resistance, liver surgery
Abstract: Liver transplantation (LT) for hepatocellular carcinoma (HCC) is the treatment of choice for patients with tumor characteristics within the Milan criteria associated with Child B or C cirrhosis. LT provides the best cure for both the tumor and the cirrhosis.
There have been several emerging reports that new-onset diabetes mellitus (NODM) after transplantation (NODAT) is one of the most negative predictive factors for low survival rate and related co-morbidities. Little is known about the onset of NODM in post-transplant patients and, overall, whether the pathogenesis of NODM differs from that known for the general population. Principally, it is still unknown whether NODAT is related to the primary hepatic disease, the surgical procedures, immunosuppressive treatments, or is it due to the donor liver. This review will focus on the identification of factors, in the setting of LT, which may lead to the development of NODM. Early prevention of these factors may abate the incidence of NODM and positively impact survival rate, and thus ameliorate the worsening of cardiovascular risk factors which usually occur after LT.Export Options
About this article
Cite this article as:
Sarno Gerardo, J. Mehta Rucha, Guardado-Mendoza Rodolfo, M. Jimenez-Ceja Lilia, De Rosa Paride and Muscogiuri Giovanna, New-onset Diabetes Mellitus: Predictive Factors and Impact on the Outcome of Patients Undergoing Liver Transplantation, Current Diabetes Reviews 2013; 9 (1) . https://dx.doi.org/10.2174/1573399811309010078
DOI https://dx.doi.org/10.2174/1573399811309010078 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Attenuation of Diabetes-induced Cardiac and Subcellular Defects by Sulphur-containing Amino Acids
Current Medicinal Chemistry Pathophysiology of Atherosclerosis: The Role of Inflammation
Current Pharmaceutical Design The Dual Role of Free Fatty Acid Signaling in Inflammation and Therapeutics
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Electronic Noses in Medical Diagnostics
Current Medicinal Chemistry Diabetes Association with Liver Diseases: An Overview for Clinicians
Endocrine, Metabolic & Immune Disorders - Drug Targets Hypertension in Peripheral Arterial Disease
Current Pharmaceutical Design Diabetic Patients with Psychiatric Illness
Current Diabetes Reviews Vascular, Oxidative, and Synaptosomal Abnormalities During Aging and the Progression of Type 2 Diabetes
Current Neurovascular Research Chiral Kinase Inhibitors
Current Topics in Medicinal Chemistry Antioxidant Mechanisms in Nonalcoholic Fatty Liver Disease
Current Drug Targets Anagliptin, A Dipeptidyl Peptidase-4 Inhibitor Ameliorates Arterial Stiffness in Association with Reduction of Remnant-Like Particle Cholesterol and Alanine Transaminase Levels in Type 2 Diabetic Patients
Current Vascular Pharmacology Fine-tuning of microRNAs in Type 2 Diabetes Mellitus
Current Medicinal Chemistry Therapeutic Strategies of Plant-derived Compounds for Diabetes Via Regulation of Monocyte Chemoattractant Protein-1
Current Medicinal Chemistry Relationship Between Non-Genomic Actions of Estrogens and Insulin Resistace
Infectious Disorders - Drug Targets Serum Hepcidin, the Hepcidin/Ferritin Ratio and the Risk of Type 2 Diabetes: A Systematic Review and Meta-Analysis
Current Medicinal Chemistry Cocoa Polyphenols: Evidence from Epidemiological Studies
Current Pharmaceutical Design Acute Cardioembolic Cerebral Infarction: Answers to Clinical Questions
Current Cardiology Reviews Targeting Aldose Reductase for the Treatment of Cancer
Current Cancer Drug Targets The Effect of Drugs and Genetic Factors on the Development and Progression of the Atherosclerotic Process
Current Vascular Pharmacology Risk and Benefit Profile of Dulaglutide in Established Therapeutic Indication
Current Drug Safety